United States Topical Pain Relief Market to Grow at a CAGR of 8.6% During 2024-2032, Aided by Growing Incidences of Chronic Pain Diseases Like Arthritis and Diabetic Neuropathy

Topical pain relief medications offer targeted relief by directly applying them over the inflamed and painful area. These formulations, containing analgesic or anaesthetic agents, gradually release medication into the bloodstream, maintaining relatively constant blood levels for sustained pain relief. They entail fewer side effects compared to oral medications, which is aiding the United States topical pain relief market.

In the U.S., the market is driven by factors like increasing arthritis prevalence, diabetic neuropathy, and the preference for topical products due to their reduced side effects.

As diabetic neuropathic pain (DNP) significantly impacts the quality of life of patients, the demand for effective medications to treat the same is increasing. While oral treatment is widely used for treating DNP, it often results in side effects. Thus, alternative methods are being explored, with topical use of drugs gaining significant interest for treating DNP.

According to the International Diabetes Federation, in the United States, there were only 15.28 million individuals affected by diabetes in 2000, which reached 32.22 million in 2021. This accounted for an increase of 111% in 21 years in the country. It is further expected to affect about 36.29 million in 2045.

Cream-based formulations are particularly popular due to their ease of use and fewer side effects. E-commerce is rapidly emerging as a key distribution channel, supported by wide internet accessibility, further fueling market growth. However, challenges like potential skin irritation and unpleasant odours exist. The rise of online platforms for topical therapeutics presents promising opportunities for the market expansion.

Further, the launch of new products is shaping the market dynamics of the US tropical pain relief market. In August 2023, Kenvue Inc. (NYSE: KVUE) launched its new Tylenol® Precise™ Pain Relieving Cream. Additionally, Kenvue will showcase Motrin® Dual Action with Tylenol®, a combination pill providing up to 8 hours of pain relief, based on consumer insights gathered by Tylenol®, the leading Doctor Recommended Brand for Pain Relief.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Market Breakup by Therapeutic Class, Formulation, Type, and Distribution Channel:

• The market is bifurcated based on therapeutic class into non-opioids and opioids.

• Based on formulation, the market can be divided into cream, gel, spray, and patch, among others.

• Based on type, the market is divided into prescription pain relief and over-the-counter pain relief.

• The major distribution channels include pharmacies and drug stores, e-commerce, and retail and grocery stores.

Key Findings of the Report:

• The U.S. market is driven by factors such as the increasing prevalence of conditions like arthritis and diabetic neuropathy.

• The preference for topical products due to their reduced side effects is expected to continue to rise.

• Cream-based formulations are popular for their ease of use and minimal side effects.

• E-commerce is emerging as a crucial distribution channel, bolstered by widespread internet accessibility.

• The launch of new products, and ongoing innovations in the market, are driven by consumer needs and the quest for effective pain relief options.

Key Offerings of the Report:

• The EMR report gives an overview of the United States topical pain relief market for the periods (2017-2023) and (2024-2032).

• The report also offers historical (2017-2023) and forecast (2024-2032) market information for the therapeutic class, formulation, type, and distribution channel of the topical pain relief market.

• The report analyses the market dynamics, covering the key demand and price indicators in the market, along with providing an assessment of the SWOT and Porter’s Five Forces models.

The major players in the United States topical pain relief market are AdvaCare Pharma, GlaxoSmithKline Plc., Johnson & Johnson Services, Inc., Pfizer Inc., Reckitt Benckiser Group PLC, Novartis AG, Sanofi, and Sun Pharmaceutical Industries Ltd., among others. The comprehensive report by EMR looks into the market share, capacity, and latest developments like mergers and acquisitions, plant turnarounds, and capacity expansions of the major players.

Key Highlights of the Report

About Us:

Expert Market Research (EMR) is a leading market research and business intelligence company, ensuring its clients remain at the vanguard of their industries by providing them with exhaustive and actionable market data through its syndicated and custom market reports, covering over 15 major industry domains. The company's expansive and ever-growing database of reports, which are constantly updated, includes reports from industry verticals like chemicals and materials, food and beverages, energy and mining, technology and media, consumer goods, pharmaceuticals, agriculture, and packaging.

EMR leverages its state-of-the-art technological and analytical tools, along with the expertise of its highly skilled team of over a 100 analysts and more than 3000 consultants, to help its clients, ranging from Fortune 1000 companies to small and medium sized enterprises, easily grasp the expansive industry data and help them in formulating market and business strategies, which ensure that they remain ahead of the curve.

Contact Us:

Expert Market Research
Website: www.expertmarketresearch.com
Email: [email protected]
US & Canada Phone no: +1-415-325-5166
UK Phone no: +44-702-402-5790

*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.